Freeline sets range for US IPO as biotech 'bananas' surge continues

By Sam Kerr
03 Aug 2020

Freeline Therapeutics, the UK gene therapeutics company, has set a pricing range for its Nasdaq listing, becoming the latest company from the red hot biotech sector to raise equity capital.

The company will sell 7.3m American Depositary Shares (ADRs) to investors for $16-$18.00 each. At base deal size, the IPO would raise gross proceeds of up to $131.4m.

JP MorganMorgan Stanley, Evercore and Wedbush PacGrow are running on the deal.

Biotech stocks have been on a ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial